相似文献
1
Harnessing the B Cell Response in Kidney Transplantation - Current State and Future Directions.
Front Immunol. 2022 Jun 9;13:903068. doi: 10.3389/fimmu.2022.903068. eCollection 2022.
2
Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
Nephrology (Carlton). 2016 Aug;21(8):700-4. doi: 10.1111/nep.12659.
3
What have we learned about how to prevent and treat antibody-mediated rejection in kidney transplantation?
Am J Transplant. 2020 Jun;20 Suppl 4:12-22. doi: 10.1111/ajt.15859.
4
Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
Transplantation. 2015 Jul;99(7):1423-30. doi: 10.1097/TP.0000000000000525.
5
Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.
Trials. 2019 Jan 11;20(1):37. doi: 10.1186/s13063-018-3158-6.
6
Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
Kidney Int. 2017 Mar;91(3):729-737. doi: 10.1016/j.kint.2016.10.040. Epub 2017 Jan 16.
7
Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR).
Am J Transplant. 2019 Mar;19(3):894-906. doi: 10.1111/ajt.15229. Epub 2019 Jan 25.
8
Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients.
J Am Soc Nephrol. 2019 Dec;30(12):2399-2411. doi: 10.1681/ASN.2019030304. Epub 2019 Oct 28.
9
Risk factors for the development of antibody-mediated rejection in highly sensitized pediatric kidney transplant recipients.
Pediatr Transplant. 2017 Dec;21(8). doi: 10.1111/petr.13042. Epub 2017 Sep 19.
10
Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation.
Am J Transplant. 2019 Feb;19(2):368-380. doi: 10.1111/ajt.15055. Epub 2018 Sep 17.
引用本文的文献
1
Comprehensive Phenotyping and Cytokine Production of Circulating B Cells Associate Resting Memory B Cells With Early Antibody-mediated Rejection in Kidney Transplant Recipients.
Transplant Direct. 2025 Mar 20;11(4):e1775. doi: 10.1097/TXD.0000000000001775. eCollection 2025 Apr.
2
Characterization of immune phenotypes in peripheral blood of adult renal transplant recipients using mass cytometry (CyTOF).
Immunohorizons. 2025 Feb 18;9(4). doi: 10.1093/immhor/vlae013.
3
CXCR5 + CD8 + T Cell-mediated Suppression of Humoral Alloimmunity and AMR in Mice Is Optimized With mTOR and Impaired With Calcineurin Inhibition.
Transplantation. 2024 Mar 1;108(3):679-692. doi: 10.1097/TP.0000000000004828. Epub 2023 Oct 24.
4
The impact of IdeS (imlifidase) on allo-specific, xeno-reactive, and protective antibodies in a sensitized rhesus macaque model.
Xenotransplantation. 2024 Jan-Feb;31(1):e12833. doi: 10.1111/xen.12833. Epub 2023 Oct 21.
5
Addition of interleukin-6 receptor blockade to carfilzomib-based desensitization in a highly sensitized nonhuman primate model.
Am J Transplant. 2022 Dec;22 Suppl 4(Suppl 4):1-11. doi: 10.1111/ajt.17208.
6
A novel method for in vitro culture and expansion of nonhuman primate B cells.
J Immunol Methods. 2022 Dec;511:113363. doi: 10.1016/j.jim.2022.113363. Epub 2022 Sep 26.
本文引用的文献
1
Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design.
Trials. 2022 Dec 22;23(1):1042. doi: 10.1186/s13063-022-06897-3.
2
Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.
Trials. 2022 Apr 8;23(1):270. doi: 10.1186/s13063-022-06198-9.
3
Shifting Clinical Trial Endpoints in Kidney Transplantation: The Rise of Composite Endpoints and Machine Learning to Refine Prognostication.
Transplantation. 2022 Aug 1;106(8):1558-1564. doi: 10.1097/TP.0000000000004107. Epub 2022 Mar 23.
4
Emerging biomarkers in kidney transplantation and challenge of clinical implementation.
Curr Opin Organ Transplant. 2022 Feb 1;27(1):15-21. doi: 10.1097/MOT.0000000000000941.
5
The Multifaceted Roles of B Cells in the Thymus: From Immune Tolerance to Autoimmunity.
Front Immunol. 2021 Nov 1;12:766698. doi: 10.3389/fimmu.2021.766698. eCollection 2021.
6
Optimal Immunosuppression Strategy in the Sensitized Kidney Transplant Recipient.
J Clin Med. 2021 Aug 18;10(16):3656. doi: 10.3390/jcm10163656.
7
Long-Term Survival after Kidney Transplantation.
N Engl J Med. 2021 Aug 19;385(8):729-743. doi: 10.1056/NEJMra2014530.
8
Donor-Specific Antibody Is Associated with Increased Expression of Rejection Transcripts in Renal Transplant Biopsies Classified as No Rejection.
J Am Soc Nephrol. 2021 Nov;32(11):2743-2758. doi: 10.1681/ASN.2021040433. Epub 2021 Jul 12.
9
Disruption of Tfh:B Cell Interactions Prevents Antibody-Mediated Rejection in a Kidney Transplant Model in Rats: Impact of Calcineurin Inhibitor Dose.
Front Immunol. 2021 May 31;12:657894. doi: 10.3389/fimmu.2021.657894. eCollection 2021.
10
Therapies for Chronic Allograft Rejection.
Front Pharmacol. 2021 Apr 15;12:651222. doi: 10.3389/fphar.2021.651222. eCollection 2021.
Zotero 插件